- Home
- RVMDW vs GALT Comparison
RVMDW vs GALT Comparison
Compare RVMDW & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVMDW
- GALT
- Stock Information
- Founded
- RVMDW N/A
- GALT 2000
- Country
- RVMDW United States
- GALT United States
- Employees
- RVMDW 490
- GALT N/A
- Industry
- RVMDW
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- RVMDW
- GALT Health Care
- Exchange
- RVMDW Nasdaq
- GALT Nasdaq
- Market Cap
- RVMDW N/A
- GALT 54.6M
- IPO Year
- RVMDW N/A
- GALT N/A
- Fundamental
- Price
- RVMDW $0.18
- GALT $1.29
- Analyst Decision
- RVMDW
- GALT Hold
- Analyst Count
- RVMDW 0
- GALT 1
- Target Price
- RVMDW N/A
- GALT N/A
- AVG Volume (30 Days)
- RVMDW N/A
- GALT 1.7M
- Earning Date
- RVMDW N/A
- GALT 11-13-2024
- Dividend Yield
- RVMDW N/A
- GALT N/A
- EPS Growth
- RVMDW N/A
- GALT N/A
- EPS
- RVMDW N/A
- GALT N/A
- Revenue
- RVMDW N/A
- GALT N/A
- Revenue This Year
- RVMDW N/A
- GALT N/A
- Revenue Next Year
- RVMDW N/A
- GALT N/A
- P/E Ratio
- RVMDW N/A
- GALT N/A
- Revenue Growth
- RVMDW N/A
- GALT N/A
- 52 Week Low
- RVMDW N/A
- GALT $0.73
- 52 Week High
- RVMDW N/A
- GALT $4.27
- Technical
- Relative Strength Index (RSI)
- RVMDW N/A
- GALT 39.16
- Support Level
- RVMDW N/A
- GALT $0.76
- Resistance Level
- RVMDW N/A
- GALT $1.47
- Average True Range (ATR)
- RVMDW 0.00
- GALT 0.25
- MACD
- RVMDW 0.00
- GALT -0.02
- Stochastic Oscillator
- RVMDW 0.00
- GALT 39.88
About RVMDW Revolution Medicines Inc. Warrant
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.